ALT A graph showing event-free survival for the durvalumab–enfortumab vedotin (EV) and control groups (intention-to-treat population).

ALT A graph showing event-free survival for the durvalumab–tremelimumab–EV and control groups (intention-to-treat population).

ALT Kaplan–Meier curves of overall survival in the intention-to-treat population, which included all the patients who had undergone randomization.

ALT Kaplan–Meier curves of progression-free survival in the intention-to-treat population.

ALT A graph shows progression-free survival as assessed by blinded independent central review.

ALT A graph showing overall survival in the intention-to-treat population.

ALT A graph showing progression-free survival, as assessed by blinded independent central review, among the patients who received divarasib and those who received control treatment (sotorasib or adagrasib).

ALT A graph showing overall survival among the patients who received divarasib and those who received control treatment (sotorasib or adagrasib).

ALT Shown are Kaplan–Meier estimates of progression-free survival in the full analysis population (Panel A), in the MET-overexpressed analysis population (Panel B), and in the MET-amplified analysis population (Panel C), as assessed by blinded independent central review according to RECIST, version 1.1. MET overexpression was defined by a MET staining intensity of 3+ in at least 90% of tumor cells on immunohistochemical analysis, and MET amplification was defined by the presence of at least 10 MET gene copies on fluorescence in situ hybridization.

ALT Shown are the Kaplan–Meier estimates of overall survival (defined as the time from randomization until death from any cause) in the full analysis population (formally tested for significance in accordance with a multiple-testing procedure).